Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21183315 | 0.89 | CYP4Z1 (0.45) | CYP4F2CYP4A11ALDH1A1KMT2AF2RL1 | |
| SCHEMBL1747384 | 0.88 | FFAR1 (0.56) | ALDH1A1ADRB2ADRB1LMNAMAPT | |
| SCHEMBL22922181 | 0.87 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1KMT2AF2RL1 | |
| SCHEMBL10083065 | 0.86 | CYP4Z1 (0.45) | CYP4F2CYP4A11ALDH1A1KMT2ACYP4Z1 | |
| SCHEMBL10055902 | 0.86 | ALDH1A1 (0.42) | CYP4F2CYP4A11ALDH1A1CYP4Z1CYP11B1 | |
| SCHEMBL15494077 | 0.85 | IDO1 (0.49) | CYP4F2CYP4A11ALDH1A1KMT2AADRB2 | |
| SCHEMBL349384 | 0.84 | CYP4F2 (0.70) | CYP4F2CYP4A11KMT2ACYP4Z1EPHX2 | |
| SCHEMBL28351306 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1KMT2AF2RL1 | |
| SCHEMBL693698 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1KMT2AF2RL1 | |
| SCHEMBL11888662 | 0.83 | FFAR1 (0.46) | ALDH1A1KMT2ACYP4Z1HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106316837-A | Preparation method for substituted phenylacetic acid derivatives | 浙江九洲药业股份有限公司 | 2017-01-11 | — | — | CN | claimed |
| CN-115595200-A | Metal lubricating cutting fluid and preparation method thereof | 安徽韩铝环保新材料有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-02-14 | — | — | US | disclosed |
| EP-3210981-B1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA 2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE RESPIRATORY CO LLC (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101767-A2 | CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6413995-B1 | IMMUNOMODULATORS | TSUMURA & CO. (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1142875-A1 | CINNAMAMIDE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-1992009561-A1 | NEW AMIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-06-11 | — | — | WO | disclosed |
| US-4713486-A | ANTIALLERGENS | BEECHAM GROUP P.L.C. (GB) | 1987-12-15 | — | — | US | disclosed |
| EP-0109225-B1 | ARACHIDONIC ACID ANALOGUES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN MEDICINE | BEECHAM GROUP PLC (GB) | 1985-08-28 | — | — | EP | disclosed |
| EP-0109225-A1 | Arachidonic acid analogues, processes for their preparation and their use in medicine | BEECHAM GROUP PLC (GB) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CYP4F2 1554/4885CYP4A11 1051/4885ALDH1A1 1263/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | CYP4F2 1433/4885CYP4A11 1100/4885ALDH1A1 1282/4885 |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | CCNI, SP1, DCK | CYP4F2 4296/4885CYP4A11 4408/4885ALDH1A1 4597/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CYP4F2 2223/4885CYP4A11 751/4885ALDH1A1 1382/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | CYP4F2 1554/4885CYP4A11 1051/4885ALDH1A1 1263/4885 |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CYP4F2 1856/4885CYP4A11 1089/4885ALDH1A1 1356/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CYP4F2 1554/4885CYP4A11 1051/4885ALDH1A1 1263/4885 |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | CYP4F2 1607/4885CYP4A11 1032/4885ALDH1A1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.